Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3626
Brilliant Earth
BRLT
$17.1M
| $548K | ﹤0.01% |
255,890
-4,746
| -2% | -$10.3K |
|
3627
CALL
Merck
MRK
$322B
| $545K | ﹤0.01% |
4,800
-149,600
| -97% | -$17.8M |
|
3628
Southern California Bancorp
BCAL
$684M
| $544K | ﹤0.01% |
36,756
+23,499
| +177% | +$342K |
|
3629
Aura Biosciences
AURA
$725M
| $544K | ﹤0.01% |
61,010
+43,897
| +257% | +$376K |
|
|
GRP.U
3630
DELISTED
Granite Real Estate Investment Trust
GRP.U
| $542K | ﹤0.01% |
8,870
-18,177
| -67% | -$1M |
|
3631
Groupon
GRPN
$1.05B
| $540K | ﹤0.01% |
55,210
-51,307
| -48% | -$688K |
|
|
CARM
3632
DELISTED
Carisma Therapeutics
CARM
| $539K | ﹤0.01% |
549,305
+549,290
| +3,661,933% | +$595K |
|
|
ACCD
3633
DELISTED
Accolade Inc
ACCD
| $539K | ﹤0.01% |
139,901
+86,981
| +164% | +$341K |
|
3634
Inogen
INGN
$175M
| $538K | ﹤0.01% |
55,508
+23,398
| +73% | +$246K |
|
3635
Denison Mines
DNN
$2.54B
| $538K | ﹤0.01% |
294,201
-2,049,399
| -87% | -$3.6M |
|
|
CGAU
3636
Centerra Gold
CGAU
$3.36B
| $536K | ﹤0.01% |
74,930
+55,444
| +285% | +$381K |
|
3637
Open Text
OTEX
$6.15B
| $535K | ﹤0.01% |
16,061
+105
| +0.7% | +$3.31K |
|
3638
Bank of Montreal
BMO
$126B
| $534K | ﹤0.01% |
5,923
+2,455
| +71% | +$209K |
|
3639
Direxion Daily Small Cap Bull 3x ETF
TNA
$1.3B
| $532K | ﹤0.01% |
12,000
-30,000
| -71% | -$1.24M |
|
3640
Pulse Biosciences
PLSE
$2.43B
| $532K | ﹤0.01% |
30,306
+23,738
| +361% | +$405K |
|
|
TBI
3641
Trueblue
TBI
$215M
| $531K | ﹤0.01% |
67,353
+32,940
| +96% | +$296K |
|
3642
Silvercrest Asset Management
SAMG
$79M
| $531K | ﹤0.01% |
30,814
+10,110
| +49% | +$163K |
|
|
DENN
3643
DELISTED
Denny's
DENN
| $531K | ﹤0.01% |
82,257
+63,668
| +343% | +$416K |
|
3644
Root
ROOT
$857M
| $530K | ﹤0.01% |
14,033
+10,993
| +362% | +$568K |
|
3645
Cricut
CRCT
$984M
| $530K | ﹤0.01% |
76,440
+60,058
| +367% | +$360K |
|
3646
Theravance Biopharma
TBPH
$874M
| $529K | ﹤0.01% |
65,580
+48,316
| +280% | +$419K |
|
3647
CALL
Cytokinetics
CYTK
$10.5B
| $528K | ﹤0.01% |
10,000
-70,000
| -88% | -$3.9M |
|
|
3648
PUT
Cytokinetics
CYTK
$10.5B
| $528K | ﹤0.01% |
+10,000
| New | +$557K |
|
3649
Kornit Digital
KRNT
$705M
| $528K | ﹤0.01% |
20,420
+11,544
| +130% | +$213K |
|
3650
Red Violet
RDVT
$979M
| $526K | ﹤0.01% |
18,502
+13,072
| +241% | +$355K |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.